Literature DB >> 21719795

Molecular signature of a right heart failure program in chronic severe pulmonary hypertension.

Jennifer I Drake1, Herman J Bogaard, Shiro Mizuno, Berrick Clifton, Bin Xie, Yuan Gao, Catherine I Dumur, Paul Fawcett, Norbert F Voelkel, Ramesh Natarajan.   

Abstract

Right heart failure is the cause of death of most patients with severe pulmonary arterial hypertensive (PAH) disorders, yet little is known about the cellular and molecular causes of right ventricular failure (RVF). We first showed a differential gene expression pattern between normal rat right and left ventricles, and postulated the existence of a molecular right heart failure program that distinguishes RVF from adaptive right ventricular hypertrophy (RVH), and that may differ in some respects from a left heart failure program. By means of microarrays and transcriptional sequencing strategies, we used two models of adaptive RVH to characterize a gene expression pattern reflective of growth and the maintenance of myocardial structure. Moreover, two models of RVF were associated with fibrosis, capillary rarefaction, the decreased expression of genes encoding the angiogenesis factors vascular endothelial growth factor, insulin-like growth factor 1, apelin, and angiopoeitin-1, and the increased expression of genes encoding a set of glycolytic enzymes. The treatment of established RVF with a β-adrenergic receptor blocker reversed RVF, and partly reversed the molecular RVF program. We conclude that normal right and left ventricles demonstrate clearly discernable differences in the expression of mRNA and microRNA, and that RVH and RVF are characterized by distinct patterns of gene expression that relate to cell growth, angiogenesis, and energy metabolism.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21719795      PMCID: PMC3361357          DOI: 10.1165/rcmb.2010-0412OC

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  54 in total

1.  A paradigm for class prediction using gene expression profiles.

Authors:  Michael D Radmacher; Lisa M McShane; Richard Simon
Journal:  J Comput Biol       Date:  2002       Impact factor: 1.479

Review 2.  Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification.

Authors:  Richard Simon; Michael D Radmacher; Kevin Dobbin; Lisa M McShane
Journal:  J Natl Cancer Inst       Date:  2003-01-01       Impact factor: 13.506

3.  Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure.

Authors:  S Ghio; A Gavazzi; C Campana; C Inserra; C Klersy; R Sebastiani; E Arbustini; F Recusani; L Tavazzi
Journal:  J Am Coll Cardiol       Date:  2001-01       Impact factor: 24.094

4.  Angiopoietin-1 regulates endothelial cell survival through the phosphatidylinositol 3'-Kinase/Akt signal transduction pathway.

Authors:  I Kim; H G Kim; J N So; J H Kim; H J Kwak; G Y Koh
Journal:  Circ Res       Date:  2000 Jan 7-21       Impact factor: 17.367

5.  Right ventricular dysfunction and risk of heart failure and mortality after myocardial infarction.

Authors:  Leonardo A M Zornoff; Hicham Skali; Marc A Pfeffer; Martin St John Sutton; Jean L Rouleau; Gervasio A Lamas; Ted Plappert; Jacques R Rouleau; Lemuel A Moyé; Sandra J Lewis; Eugene Braunwald; Scott D Solomon
Journal:  J Am Coll Cardiol       Date:  2002-05-01       Impact factor: 24.094

6.  The combinatorial activities of Nkx2.5 and dHAND are essential for cardiac ventricle formation.

Authors:  H Yamagishi; C Yamagishi; O Nakagawa; R P Harvey; E N Olson; D Srivastava
Journal:  Dev Biol       Date:  2001-11-15       Impact factor: 3.582

7.  Cardiac chamber-specific alterations of ANP and BNP expression with advancing age and with systemic hypertension.

Authors:  V Raizada; K Thakore; W Luo; P G McGuire
Journal:  Mol Cell Biochem       Date:  2001-01       Impact factor: 3.396

8.  The inhibition of pyruvate dehydrogenase kinase improves impaired cardiac function and electrical remodeling in two models of right ventricular hypertrophy: resuscitating the hibernating right ventricle.

Authors:  Lin Piao; Yong-Hu Fang; Virgilio J J Cadete; Christian Wietholt; Dalia Urboniene; Peter T Toth; Glenn Marsboom; Hannah J Zhang; Idith Haber; Jalees Rehman; Gary D Lopaschuk; Stephen L Archer
Journal:  J Mol Med (Berl)       Date:  2009-12-01       Impact factor: 4.599

9.  The pathophysiology of failure in acute right ventricular hypertension: hemodynamic and biochemical correlations.

Authors:  G J Vlahakes; K Turley; J I Hoffman
Journal:  Circulation       Date:  1981-01       Impact factor: 29.690

10.  Natriuretic peptides as cardiac hormones in normotensive and spontaneously hypertensive rats. The ventricle is a major site of synthesis and secretion of brain natriuretic peptide.

Authors:  Y Ogawa; K Nakao; M Mukoyama; K Hosoda; G Shirakami; H Arai; Y Saito; S Suga; M Jougasaki; H Imura
Journal:  Circ Res       Date:  1991-08       Impact factor: 17.367

View more
  88 in total

Review 1.  Pathobiology of pulmonary arterial hypertension and right ventricular failure.

Authors:  Norbert F Voelkel; Jose Gomez-Arroyo; Antonio Abbate; Harm J Bogaard; Mark R Nicolls
Journal:  Eur Respir J       Date:  2012-06-27       Impact factor: 16.671

2.  Right ventricular protein expression profile in end-stage heart failure.

Authors:  Yan Ru Su; Manuel Chiusa; Evan Brittain; Anna R Hemnes; Tarek S Absi; Chee Chew Lim; Thomas G Di Salvo
Journal:  Pulm Circ       Date:  2015-09       Impact factor: 3.017

Review 3.  The right ventricle and pulmonary hypertension.

Authors:  Mariëlle C van de Veerdonk; Harm J Bogaard; Norbert F Voelkel
Journal:  Heart Fail Rev       Date:  2016-05       Impact factor: 4.214

4.  Characterization of right ventricular remodeling and failure in a chronic pulmonary hypertension model.

Authors:  Jaume Aguero; Kiyotake Ishikawa; Lahouaria Hadri; Carlos Santos-Gallego; Kenneth Fish; Nadjib Hammoudi; Antoine Chaanine; Samantha Torquato; Charbel Naim; Borja Ibanez; Daniel Pereda; Ana García-Alvarez; Valentin Fuster; Partho P Sengupta; Jane A Leopold; Roger J Hajjar
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-08-22       Impact factor: 4.733

Review 5.  The apelinergic system: a perspective on challenges and opportunities in cardiovascular and metabolic disorders.

Authors:  Eric Marsault; Catherine Llorens-Cortes; Xavier Iturrioz; Hyung J Chun; Olivier Lesur; Gavin Y Oudit; Mannix Auger-Messier
Journal:  Ann N Y Acad Sci       Date:  2019-06-25       Impact factor: 5.691

6.  Multiscale structure-function relationships in right ventricular failure due to pressure overload.

Authors:  Tik-Chee Cheng; Jennifer L Philip; Diana M Tabima; Timothy A Hacker; Naomi C Chesler
Journal:  Am J Physiol Heart Circ Physiol       Date:  2018-06-08       Impact factor: 4.733

7.  ERG-APLNR axis controls pulmonary venule endothelial proliferation in pulmonary veno-occlusive disease.

Authors:  Christopher Lathen; Yu Zhang; Jennifer Chow; Martanday Singh; Grace Lin; Vishal Nigam; Yasser A Ashraf; Jason X Yuan; Ivan M Robbins; Patricia A Thistlethwaite
Journal:  Circulation       Date:  2014-07-25       Impact factor: 29.690

Review 8.  Fibroblasts and the extracellular matrix in right ventricular disease.

Authors:  Nikolaos G Frangogiannis
Journal:  Cardiovasc Res       Date:  2017-10-01       Impact factor: 10.787

9.  Serum endostatin is a genetically determined predictor of survival in pulmonary arterial hypertension.

Authors:  Rachel Damico; Todd M Kolb; Lidenys Valera; Lan Wang; Traci Housten; Ryan J Tedford; David A Kass; Nicholas Rafaels; Li Gao; Kathleen C Barnes; Raymond L Benza; James L Rand; Rizwan Hamid; James E Loyd; Ivan M Robbins; Anna R Hemnes; Wendy K Chung; Eric D Austin; M Bradley Drummond; Stephen C Mathai; Paul M Hassoun
Journal:  Am J Respir Crit Care Med       Date:  2015-01-15       Impact factor: 21.405

Review 10.  Novel therapeutic approaches to preserve the right ventricle.

Authors:  Samar Farha; Erika L Lundgrin; Serpil C Erzurum
Journal:  Curr Heart Fail Rep       Date:  2013-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.